Moteur de recherche d’entreprises européennes
Financement de l’UE (183 455 €) : Modulation et profilage de la S-palmitoylation du récepteur Tyrosine Kinase S-dans le cancer du sein Hor22/03/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Modulation et profilage de la S-palmitoylation du récepteur Tyrosine Kinase S-dans le cancer du sein
Breast cancer is one of the most diagnosed cancers and the leading cause of cancer death in women worldwide. Breast cancer cells need activated receptor tyrosine kinases (RTKs) to invade, proliferate, and metastasize. Increased activity and overexpression of RTKs is associated with poor prognosis for breast cancer patients. Therefore, multiple RTKs have emerged as attractive therapeutic targets. However, resistance to therapies is a persistent problem for the development of therapeutics targeting RTKs. New and innovative approaches to effectively target these receptors are required. Recently S-palmitoylation has been identified as an important post-translational modification that regulates signal transduction, protein trafficking and degradation of specific RTKs in breast cancer. The substrate scope, role, extent of dysregulation and the enzymes responsible for the S-palmitoylation of specific substrates in breast cancer is largely unknown. In this context, the aim of the proposed project is to implement novel chemical biological tools and methods, to gain insight in the extent, regulation and role of S-palmitoylation of RTKs in breast cancer. This insight will facilitate the identification of new approaches to therapeutically target RTKs in breast cancer.
| Imperial College of Science Technology and Medicine | 183 455 € |
https://cordis.europa.eu/project/id/750409
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Imperial College of Science Technology and Medicine, Londres, Royaume Uni.
